Fig. 6.

Omics applications in cancer immunotherapy. Cancer immunotherapy exploits the fact that genetic aberrations in the cancer genome can result in new antigens (neoantigens) not normally expressed in benign tissue. Researchers can sequence the tumor genome to identify potential neoantigens, use proteomic methods to characterize the expressed neoantigens, and design personalized cancer vaccines based on the identified neoantigens, which will elicit specific immune response against the tumor cells.